Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib vs lapatinib + capecitabine as second-line therapy in HER2-positive metastatic gastro-esophageal cancer
2009-009894-88Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Jun 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Lapatinib monotherapy with Lapatinib + capecitabine (2 arms). Primary endpoint: Objective response rate. Started Jun 2009; status: completed.
02
Drugs
lapatinibcapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2009-009894-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009894-88.